The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs, And Conference Presentations In The Spotlight

TCT Meeting Presentations:

  • Gamida Cell Ltd (GMDA): results of the Phase 1 study of omidubicel versus standard myeloblative umbilical cord blood transplantation in patients with hematologic malignancies undergoing allogeneic bone marrow transplant (Tuesday, Feb. 9 at 4:45-5 p.m.).
  • Equillium Inc (EQ): interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (Friday, Feb. 12, 3 p.m.).
  • Takeda Pharmaceutical Co Ltd (TAK): Phase 3 data for TAK-620 in the treatment of transplant recipients with refractory/resistant cytomegalovirus infections (Friday, Feb. 12).

ASCO Genitourinary Cancers Symposium Presentations:

  • Clovis Oncology Inc (CLVS): Pharmacokinetics and safety data from the phase 1b RAMP study evaluating rucaparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer (Thursday, Feb. 11, 8 a.m.).
  • Infinity Pharmaceuticals Inc. (INFI): Preliminary analysis of a phase 2 data for eganelisib in combination with and Bristol-Myers Squibb Co (BMY)'s Opdivo compared to Opdivo monotherapy in patients with advanced urothelial carcinoma (Thursday, Feb. 11).
  • BioXcel Therapeutics Inc (BTAI): updated Phase 1b/2 data for BXCL701 in combination with Merck & Co., Inc. (MRK)'s Keytruda in men with metastatic castration-resistant prostate cancer (Thursday, Feb. 11, 8 a.m.).

Angiogenesis, Exudation, and Degeneration 2021 Conference Presentation:

  • Kodiak Sciences Inc (KOD): Clinical data on its investigational therapy KSI-301 in wet age-related macular degeneration and retinal vascular diseases (Saturday, Feb. 13 at 8:30 a.m.).


Monday, Feb. 8:

  • Corcept Therapeutics Incorporated (CORT) (after the market close).
  • Enanta Pharmaceuticals Inc (ENTA) (after the market close).

Tuesday, Feb. 9:

  • Incyte Corporation (INCY) (before the market open).
  • Deciphera Pharmaceuticals Inc (DCPH) (before the market open).
  • SurModics, Inc. (SRDX) (before the market open).
View single page >> |

© 2021 Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.